Acurx Pharmaceuticals (ACXP) Expected to Announce Earnings on Friday

Acurx Pharmaceuticals (NASDAQ:ACXP) is anticipated to announce its Q4 2025 results before the market opens on Friday, March 13th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 8:00 AM ET.

Acurx Pharmaceuticals Stock Performance

NASDAQ:ACXP opened at $2.90 on Wednesday. The firm has a market cap of $7.40 million, a P/E ratio of -0.34 and a beta of -1.16. Acurx Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $21.00. The firm has a 50-day simple moving average of $2.25 and a two-hundred day simple moving average of $3.81.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ACXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Acurx Pharmaceuticals has an average rating of “Hold” and a consensus price target of $31.00.

Institutional Trading of Acurx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Acurx Pharmaceuticals in the 4th quarter worth $27,000. Geode Capital Management LLC purchased a new stake in Acurx Pharmaceuticals during the fourth quarter valued at approximately $31,000. Armistice Capital LLC acquired a new stake in shares of Acurx Pharmaceuticals in the 2nd quarter worth $551,000. Finally, Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals during the fourth quarter worth about $103,000. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).